HR5526Referred to Committee

Biosimilar Red Tape Elimination Act

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-09-19
Introduced
7
Cosponsors
HR
ⓘ
Type

Sponsor

August Pfluger
August Pfluger
Republican · TX · Representative
Votes with party: 98.9% (545 recorded votes)

Full profile: /officials/P000048

Source: Congress.gov · FEC

Cosponsors (7)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the House Committee on Energy and Commerce.

2025-09-19

Source: Congress.gov

Committee Activity

Currently in

Plain-English Summary

This bill would streamline the approval process for biosimilar drugs—cheaper alternatives to expensive biologic medications—by reducing regulatory requirements and paperwork that manufacturers must complete. The goal is to get these more affordable treatment options to patients faster and make it easier for drug makers to bring them to market, which could lower costs for patients and insurance companies paying for medications like cancer treatments and arthritis drugs.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.